Suivre
Peter Boström
Peter Boström
Turku University Hospital
Adresse e-mail validée de tyks.fi
Titre
Citée par
Citée par
Année
Genomic predictors of outcome in prostate cancer
PJ Boström, AS Bjartell, JWF Catto, SE Eggener, H Lilja, S Loeb, ...
European urology 68 (6), 1033-1044, 2015
2142015
Risk factors for mortality and morbidity related to radical cystectomy
PJ Boström, J Kössi, M Laato, M Nurmi
BJU international 103 (2), 191-196, 2009
1912009
Nutraceuticals and prostate cancer prevention: a current review
G Trottier, PJ Boström, N Lawrentschuk, NE Fleshner
Nature Reviews Urology 7 (1), 21-30, 2010
1552010
Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: preliminary findings from a multi‐institutional study
SB Ginsburg, A Algohary, S Pahwa, V Gulani, L Ponsky, HJ Aronen, ...
Journal of Magnetic Resonance Imaging 46 (1), 184-193, 2017
1402017
Radiomics and machine learning of multisequence multiparametric prostate MRI: Towards improved non-invasive prostate cancer characterization
J Toivonen, I Montoya Perez, P Movahedi, H Merisaari, M Pesola, ...
PloS one 14 (7), e0217702, 2019
1032019
Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial)
I Jambor, PJ Boström, P Taimen, K Syvänen, E Kähkönen, M Kallajoki, ...
Journal of Magnetic Resonance Imaging 46 (4), 1089-1095, 2017
982017
Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort
G Trottier, MJ Roobol, N Lawrentschuk, PJ Boström, KA Fernandes, ...
BJU international 108 (8b), E237-E244, 2011
972011
Randomised trial of adjuvant radiotherapy following radical prostatectomy versus radical prostatectomy alone in prostate cancer patients with positive margins or extracapsular …
G Hackman, K Taari, TL Tammela, M Matikainen, M Kouri, T Joensuu, ...
European urology 76 (5), 586-595, 2019
952019
Evaluation of different mathematical models for diffusion‐weighted imaging of normal prostate and prostate cancer using high b‐values: a repeatability study
I Jambor, H Merisaari, P Taimen, P Boström, H Minn, M Pesola, ...
Magnetic resonance in medicine 73 (5), 1988-1998, 2015
912015
Expression of collagenase‐3 (matrix metalloproteinase‐13) in transitional‐cell carcinoma of the urinary bladder
PJ Boström, L Ravanti, N Reunanen, V Aaltonen, KO Söderström, ...
International journal of cancer 88 (3), 417-423, 2000
892000
Mathematical models for diffusion‐weighted imaging of prostate cancer using b values up to 2000 s/mm2: Correlation with Gleason score and repeatability of …
J Toivonen, H Merisaari, M Pesola, P Taimen, PJ Boström, T Pahikkala, ...
Magnetic resonance in medicine 74 (4), 1116-1124, 2015
832015
A prospective comparison of 18F-prostate-specific membrane antigen-1007 positron emission tomography computed tomography, whole-body 1.5 T magnetic resonance imaging with …
M Anttinen, O Ettala, S Malaspina, I Jambor, M Sandell, S Kajander, ...
European urology oncology 4 (4), 635-644, 2021
792021
Fitting methods for intravoxel incoherent motion imaging of prostate cancer on region of interest level: Repeatability and gleason score prediction
H Merisaari, P Movahedi, IM Perez, J Toivonen, M Pesola, P Taimen, ...
Magnetic resonance in medicine 77 (3), 1249-1264, 2017
782017
Tumor-associated macrophages provide significant prognostic information in urothelial bladder cancer
MM Boström, H Irjala, T Mirtti, P Taimen, T Kauko, A Ålgars, S Jalkanen, ...
PloS one 10 (7), e0133552, 2015
762015
Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial)
I Jambor, A Kuisma, E Kähkönen, J Kemppainen, H Merisaari, O Eskola, ...
European journal of nuclear medicine and molecular imaging 45, 355-364, 2018
732018
Combined use of prostate-specific antigen density and magnetic resonance imaging for prostate biopsy decision planning: a retrospective multi-institutional study using the …
UG Falagario, I Jambor, A Lantz, O Ettala, A Stabile, P Taimen, HJ Aronen, ...
European urology oncology 4 (6), 971-979, 2021
672021
Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: a prospective multi-institutional trial
I Jambor, J Verho, O Ettala, J Knaapila, P Taimen, KT Syvänen, ...
PLoS medicine 16 (6), e1002813, 2019
592019
Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy
K Lahdensuo, A Erickson, I Saarinen, H Seikkula, J Lundin, M Lundin, ...
Modern Pathology 29 (12), 1565-1574, 2016
562016
SORLA regulates endosomal trafficking and oncogenic fitness of HER2
M Pietilä, P Sahgal, E Peuhu, NZ Jäntti, I Paatero, E Närvä, H Al-Akhrass, ...
Nature Communications 10 (1), 2340, 2019
552019
Validation of novel biomarkers for prostate cancer progression by the combination of bioinformatics, clinical and functional studies
S Alinezhad, RM Väänänen, J Mattsson, Y Li, T Tallgren, N Tong Ochoa, ...
PloS one 11 (5), e0155901, 2016
532016
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20